{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:32:36Z","timestamp":1783402356217,"version":"3.54.6"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"DOI":"10.1007\/s00223-024-01250-z","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T12:01:42Z","timestamp":1721044902000},"page":"229-241","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Burosumab Efficacy and Safety in Patients with X-Linked Hypophosphatemia: Systematic Review and Meta-analysis of Real-World Data"],"prefix":"10.1007","volume":"115","author":[{"given":"Damiani","family":"Kiafzezi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athina","family":"Stamati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Karagiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios G.","family":"Goulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Christoforidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,15]]},"reference":[{"key":"1250_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1014-8","author":"SS Beck-Nielsen","year":"2019","unstructured":"Beck-Nielsen SS, Mughal Z, Haffner D et al (2019) FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J Rare Dis. https:\/\/doi.org\/10.1186\/s13023-019-1014-8","journal-title":"Orphanet J Rare Dis"},{"key":"1250_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1210\/clinem\/dgac488","volume":"108","author":"SA Ackah","year":"2023","unstructured":"Ackah SA, Imel EA (2023) Approach to hypophosphatemic rickets. J Clin Endocrinol Metab 108:209\u2013220. https:\/\/doi.org\/10.1210\/clinem\/dgac488","journal-title":"J Clin Endocrinol Metab"},{"key":"1250_CR3","doi-asserted-by":"publisher","first-page":"R57","DOI":"10.1530\/JME-20-0089","volume":"66","author":"S Fukumoto","year":"2021","unstructured":"Fukumoto S (2021) FGF23-related hypophosphatemic rickets\/osteomalacia: diagnosis and new treatment. J Mol Endocrinol 66:R57\u2013R65","journal-title":"J Mol Endocrinol"},{"key":"1250_CR4","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340","volume":"26","author":"TO Carpenter","year":"2011","unstructured":"Carpenter TO, Imel EA, Holm IA et al (2011) A clinician\u2019s guide to X-linked hypophosphatemia. J Bone Miner Res 26:1381\u20131388","journal-title":"J Bone Miner Res"},{"key":"1250_CR5","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s10545-018-0147-6","volume":"41","author":"D Chesher","year":"2018","unstructured":"Chesher D, Oddy M, Darbar U et al (2018) Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations. J Inherit Metab Dis 41:865\u2013876. https:\/\/doi.org\/10.1007\/s10545-018-0147-6","journal-title":"J Inherit Metab Dis"},{"key":"1250_CR6","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1056\/nejmoa1106173","volume":"366","author":"MP Whyte","year":"2012","unstructured":"Whyte MP, Greenberg CR, Salman NJ et al (2012) Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med 366:904\u2013913. https:\/\/doi.org\/10.1056\/nejmoa1106173","journal-title":"N Engl J Med"},{"key":"1250_CR7","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1210\/clinem\/dgab729","volume":"107","author":"A Linglart","year":"2022","unstructured":"Linglart A, Imel EA, Whyte MP et al (2022) Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia. J Clin Endocrinol Metab 107:813\u2013824. https:\/\/doi.org\/10.1210\/clinem\/dgab729","journal-title":"J Clin Endocrinol Metab"},{"key":"1250_CR8","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1530\/ec-13-0103","volume":"3","author":"A Linglart","year":"2014","unstructured":"Linglart A, Biosse-Duplan M, Briot K et al (2014) Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect 3:R13\u2013R30. https:\/\/doi.org\/10.1530\/ec-13-0103","journal-title":"Endocr Connect"},{"issue":"1","key":"1250_CR9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1210\/clinem\/dgad440","volume":"109","author":"S Wang","year":"2023","unstructured":"Wang S, Wang X, He M et al (2023) Efficacy and safety of burosumab in X-linked hypophosphatemia. J Clin Endocrinol Metab 109(1):293\u2013302. https:\/\/doi.org\/10.1210\/clinem\/dgad440","journal-title":"J Clin Endocrinol Metab"},{"key":"1250_CR10","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.3475","volume":"33","author":"KL Insogna","year":"2018","unstructured":"Insogna KL, Briot K, Imel EA et al (2018) A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res 33:1381\u20131382","journal-title":"J Bone Miner Res"},{"key":"1250_CR11","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1172\/JCI72829","volume":"124","author":"TO Carpenter","year":"2014","unstructured":"Carpenter TO, Imel EA, Ruppe MD et al (2014) Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Investig 124:1587\u20131597. https:\/\/doi.org\/10.1172\/JCI72829","journal-title":"J Clin Investig"},{"key":"1250_CR12","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s00223-020-00797-x","volume":"108","author":"R Padidela","year":"2021","unstructured":"Padidela R, Whyte MP, Glorieux FH et al (2021) Patient-reported outcomes from a randomized, active-controlled, open-label, phase 3 trial of burosumab versus conventional therapy in children with X-linked hypophosphatemia. Calcif Tissue Int 108:622\u2013633. https:\/\/doi.org\/10.1007\/s00223-020-00797-x","journal-title":"Calcif Tissue Int"},{"issue":"7","key":"1250_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097","journal-title":"PLoS Med"},{"key":"1250_CR14","unstructured":"www.metaxis.com. PROSPERO International prospective register of systematic reviews"},{"key":"1250_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.bone.2019.02.010","volume":"122","author":"TD Thacher","year":"2019","unstructured":"Thacher TD, Pettifor JM, Tebben PJ et al (2019) Rickets severity predicts clinical outcomes in children with X-linked hypophosphatemia: utility of the radiographic rickets severity score. Bone 122:76\u201381. https:\/\/doi.org\/10.1016\/j.bone.2019.02.010","journal-title":"Bone"},{"key":"1250_CR16","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/tropej\/46.3.132","volume":"46","author":"TD Thacher","year":"2000","unstructured":"Thacher TD, Fischer PR, Pettifor JM et al (2000) Radiographic scoring method for the assessment of the severity of nutritional rickets. J Trop Pediatr 46:132\u2013139. https:\/\/doi.org\/10.1093\/tropej\/46.3.132","journal-title":"J Trop Pediatr"},{"key":"1250_CR17","first-page":"1833","volume":"15","author":"NBWGCCJSLW Bellamy","year":"1998","unstructured":"Bellamy NBWGCCJSLW (1998) Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15:1833\u20131840","journal-title":"J Rheumatol"},{"key":"1250_CR18","unstructured":"Rohatgi A (2021) WebPlotDigitizer Pacifica, California, USA [07\/11\/2021]. Version: 4.5. Available from: https:\/\/automeris.io\/WebPlotDigitizer"},{"key":"1250_CR19","unstructured":"Higgins JPT, Li T, Deeks JJ (eds) (2023) Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). Cochrane. Available from www.training.cochrane.org\/handbook"},{"key":"1250_CR20","unstructured":"Deeks JJ, Higgins JPT, Altman DG (eds) (2023) Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). Cochrane. Available from www.training.cochrane.org\/handbook"},{"key":"1250_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ (Online) 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ (Online)"},{"key":"1250_CR22","unstructured":"Sterne JAC, Hern\u00e1n MA, McAleenan A, Reeves BC, Higgins JPT (2023) Chapter 25: Assessing risk of bias in a non-randomized study. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). Cochrane. Available from www.training.cochrane.org\/handbook"},{"issue":"1","key":"1250_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1164","volume":"7","author":"AA Veroniki","year":"2016","unstructured":"Veroniki AA, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G et al (2016) Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods 7(1):55\u201379","journal-title":"Res Synth Methods"},{"key":"1250_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000501868","volume":"91","author":"J Sandy","year":"2019","unstructured":"Sandy J (2019) Abstracts. Horm Res Paediatr 91:1\u2013682. https:\/\/doi.org\/10.1159\/000501868","journal-title":"Horm Res Paediatr"},{"key":"1250_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000518849","volume":"94","author":"AA Shammari","year":"2021","unstructured":"Shammari AA (2021) Abstracts. Horm Res. Paediatr 94:1\u2013445. https:\/\/doi.org\/10.1159\/000518849","journal-title":"Paediatr"},{"key":"1250_CR26","first-page":"40","volume":"96","author":"G Baroncelli","year":"2022","unstructured":"Baroncelli G (2022) Abstracts. Horm Res Paediatr 96:40","journal-title":"Horm Res Paediatr"},{"key":"1250_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000501868","volume":"91","author":"V Zhukouskaya","year":"2019","unstructured":"Zhukouskaya V (2019) Abstracts. Horm Res Paediatr 91:1\u2013682","journal-title":"Horm Res Paediatr"},{"issue":"8","key":"1250_CR28","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.3390\/jcm12082906","volume":"12","author":"T Arcidiacono","year":"2023","unstructured":"Arcidiacono T, Foligno NE, Brioni E et al (2023) Different efficacy of burosumab on physical performance and serum phosphate in adult patients with X-linked hyphophosphatemic rickets during the first six-month of treatment. J Clin Med 12(8):2906. https:\/\/doi.org\/10.3390\/jcm12082906","journal-title":"J Clin Med"},{"key":"1250_CR29","doi-asserted-by":"publisher","DOI":"10.1177\/20420188211001150","author":"A Brener","year":"2021","unstructured":"Brener A, Lebenthal Y, Cleper R et al (2021) Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy. Ther Adv Endocrinol Metab. https:\/\/doi.org\/10.1177\/20420188211001150","journal-title":"Ther Adv Endocrinol Metab"},{"key":"1250_CR30","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1210\/clinem\/dgac518","volume":"108","author":"TJ Weber","year":"2023","unstructured":"Weber TJ, Imel EA, Carpenter TO et al (2023) Long-term burosumab administration is safe and effective in adults with X-linked hypophosphatemia. J Clin Endocrinol Metab 108:155\u2013165. https:\/\/doi.org\/10.1210\/clinem\/dgac518","journal-title":"J Clin Endocrinol Metab"},{"key":"1250_CR31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","volume":"7","author":"MP Whyte","year":"2019","unstructured":"Whyte MP, Carpenter TO, Gottesman GS et al (2019) Efficacy and safety of burosumab in children aged 1\u20134 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet Diabetes Endocrinol 7:189\u2013199. https:\/\/doi.org\/10.1016\/S2213-8587(18)30338-3","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1250_CR32","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1210\/jc.2015-1551","volume":"100","author":"EA Imel","year":"2015","unstructured":"Imel EA, Zhang X, Ruppe MD et al (2015) Prolonged correction of serum phosphorus in adults with x-linked hypophosphatemia using monthly doses of KRN23. J Clin Endocrinol Metab 100:2565\u20132573. https:\/\/doi.org\/10.1210\/jc.2015-1551","journal-title":"J Clin Endocrinol Metab"},{"key":"1250_CR33","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1002\/jbmr.3843","volume":"34","author":"KL Insogna","year":"2019","unstructured":"Insogna KL, Rauch F, Kamenick\u00fd P et al (2019) Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a phase 3, single-arm, international trial. J Bone Miner Res 34:2183\u20132191. https:\/\/doi.org\/10.1002\/jbmr.3843","journal-title":"J Bone Miner Res"},{"key":"1250_CR34","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvac021","author":"N Namba","year":"2022","unstructured":"Namba N, Kubota T, Muroya K et al (2022) Safety and efficacy of burosumab in pediatric patients with X-linked hypophosphatemia: a phase 3\/4 open-label trial. J Endocr Soc. https:\/\/doi.org\/10.1210\/jendso\/bvac021","journal-title":"J Endocr Soc"},{"key":"1250_CR35","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1007\/s00467-022-05484-7","volume":"37","author":"NJ Paloian","year":"2022","unstructured":"Paloian NJ, Nemeth B, Sharafinski M et al (2022) Real-world effectiveness of burosumab in children with X-linked hypophosphatemic rickets. Pediatr Nephrol 37:2667\u20132677. https:\/\/doi.org\/10.1007\/s00467-022-05484-7","journal-title":"Pediatr Nephrol"},{"key":"1250_CR36","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.bonr.2016.05.004","volume":"5","author":"MD Ruppe","year":"2016","unstructured":"Ruppe MD, Zhang X, Imel EA et al (2016) Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia. Bone Rep 5:158\u2013162. https:\/\/doi.org\/10.1016\/j.bonr.2016.05.004","journal-title":"Bone Rep"},{"key":"1250_CR37","doi-asserted-by":"publisher","first-page":"e998","DOI":"10.1210\/clinem\/dgad223","volume":"108","author":"A Ewert","year":"2023","unstructured":"Ewert A, Rehberg M, Schlingmann KP et al (2023) Effects of burosumab treatment on mineral metabolism in children and adolescents with X-linked hypophosphatemia. J Clin Endocrinol Metab 108:e998\u2013e1006. https:\/\/doi.org\/10.1210\/clinem\/dgad223","journal-title":"J Clin Endocrinol Metab"},{"key":"1250_CR38","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3389\/fped.2020.00048","volume":"8","author":"S Mart\u00edn Ramos","year":"2020","unstructured":"Mart\u00edn Ramos S, Gil-Calvo M, Rold\u00e1n V et al (2020) Positive response to one-year treatment with burosumab in pediatric patients with X-linked hypophosphatemia. Front Pediatr 8:48. https:\/\/doi.org\/10.3389\/fped.2020.00048","journal-title":"Front Pediatr"},{"key":"1250_CR39","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/j.1365-2265.2010.03919.x","volume":"74","author":"MD Ruppe","year":"2011","unstructured":"Ruppe MD, Brosnan PG, Au KS et al (2011) Mutational analysis of PHEX, FGF23 and DMP1 in a cohort of patients with hypophosphatemic rickets. Clin Endocrinol (Oxf) 74:312\u2013318. https:\/\/doi.org\/10.1111\/j.1365-2265.2010.03919.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1250_CR40","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1681\/ASN.2005050573","volume":"16","author":"EA Imel","year":"2005","unstructured":"Imel EA, Econs MJ (2005) Fibroblast growth factor 23: roles in health and disease. J Am Soc Nephrol 16:2565\u20132575","journal-title":"J Am Soc Nephrol"},{"key":"1250_CR41","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","volume":"393","author":"EA Imel","year":"2019","unstructured":"Imel EA, Glorieux FH, Whyte MP et al (2019) Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. The Lancet 393:2416\u20132427. https:\/\/doi.org\/10.1016\/S0140-6736(19)30654-3","journal-title":"The Lancet"},{"key":"1250_CR42","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3389\/fendo.2020.00338","volume":"11","author":"A Schindeler","year":"2020","unstructured":"Schindeler A, Biggin A, Munns CF (2020) Clinical evidence for the benefits of burosumab therapy for X-linked hypophosphatemia (XLH) and other conditions in adults and children. Front Endocrinol (Lausanne) 11:338","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1250_CR43","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","volume":"105","author":"AA Portale","year":"2019","unstructured":"Portale AA, Carpenter TO, Brandi ML et al (2019) Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period. Calcif Tissue Int 105:271\u2013284. https:\/\/doi.org\/10.1007\/s00223-019-00568-3","journal-title":"Calcif Tissue Int"},{"key":"1250_CR44","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/nejmoa1714641","volume":"378","author":"TO Carpenter","year":"2018","unstructured":"Carpenter TO, Whyte MP, Imel EA et al (2018) Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med 378:1987\u20131998. https:\/\/doi.org\/10.1056\/nejmoa1714641","journal-title":"N Engl J Med"},{"key":"1250_CR45","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad440","author":"S Wang","year":"2023","unstructured":"Wang S, Wang X, He M et al (2023) Efficacy and safety of burosumab in X-linked hypophosphatemia. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgad440","journal-title":"J Clin Endocrinol Metab"},{"key":"1250_CR46","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3390\/biomedicines9070738","volume":"9","author":"C Gentile","year":"2021","unstructured":"Gentile C, Chiarelli F (2021) Rickets in children: an update. Biomedicines 9:738. https:\/\/doi.org\/10.3390\/biomedicines9070738","journal-title":"Biomedicines"},{"key":"1250_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.115964","volume":"148","author":"R Lim","year":"2021","unstructured":"Lim R, Shailam R, Hulett R et al (2021) Validation of the radiographic global impression of change (RGI-C) score to assess healing of rickets in pediatric X-linked hypophosphatemia (XLH). Bone 148:115964. https:\/\/doi.org\/10.1016\/j.bone.2021.115964","journal-title":"Bone"},{"issue":"11","key":"1250_CR48","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1210\/clinem\/dgad230","volume":"108","author":"EA Imel","year":"2023","unstructured":"Imel EA, Glorieux FH, Whyte MP et al (2023) Burosumab vs phosphate\/active vitamin D in pediatric X-linked hypophosphatemia: a subgroup analysis by dose level. J Clin Endocrinol Metab 108(11):2990\u20132998. https:\/\/doi.org\/10.1210\/clinem\/dgad230","journal-title":"J Clin Endocrinol Metab"},{"key":"1250_CR49","unstructured":"Adam MP, Feldman J, Mirzaa GM (2012) X-linked hypophosphatemia synonyms: XLHR, X-linked hypophosphatemic rickets, X-linked vitamin D-resistant rickets summary clinical characteristics. GeneReviews\u00ae [Internet] https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1384\/"},{"key":"1250_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jbo.2017.09.001","volume":"9","author":"S D\u2019Oronzo","year":"2017","unstructured":"D\u2019Oronzo S, Brown J, Coleman R (2017) The role of biomarkers in the management of bone-homing malignancies. J Bone Oncol 9:1\u20139","journal-title":"J Bone Oncol"},{"key":"1250_CR51","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/B978-0-12-814841-9.00066-X","volume-title":"Principles of bone biology (fourth edition)","author":"MP Whyte","year":"2020","unstructured":"Whyte MP (2020) Chapter 66 - Hypophosphatasia: nature\u2019s window on alkaline phosphatase function in humans. In: Bilezikian JP, Martin TJ, Clemens TL, Rosen CJ (eds) Principles of bone biology (fourth edition). Academic Press, pp 1569\u20131599"},{"key":"1250_CR52","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3945\/ajcn.111.031070","volume":"95","author":"L Tripkovic","year":"2012","unstructured":"Tripkovic L, Lambert H, Hart K et al (2012) Comparison of vitamin D2and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. Am J Clin Nutr 95:1357\u20131364","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"1250_CR53","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1177\/000456329803500203","volume":"35","author":"RB Payne","year":"1998","unstructured":"Payne RB, Bijvoet O (1998) Renal tubular reabsorption of phosphate (TmPjGFR): indications and interpretation. Ann Clin Biochem 35(2):201\u2013206","journal-title":"Ann Clin Biochem"},{"key":"1250_CR54","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/S1063-4584(03)00089-X","volume":"11","author":"F Salaffi","year":"2003","unstructured":"Salaffi F, Leardini G, Canesi B et al (2003) Reliability and validity of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index in Italian patients with osteoarthritis of the knee. Osteoarthr Cartil 11:551\u2013560. https:\/\/doi.org\/10.1016\/S1063-4584(03)00089-X","journal-title":"Osteoarthr Cartil"},{"key":"1250_CR55","unstructured":"Organising Committee Nils Krone P, Paul Van Trotsenburg C 61st Annual meeting of the European Society for Paediatric Endocrinology (ESPE)"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-024-01250-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-024-01250-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-024-01250-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T13:06:13Z","timestamp":1724072773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-024-01250-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":55,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["1250"],"URL":"https:\/\/doi.org\/10.1007\/s00223-024-01250-z","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,15]]},"assertion":[{"value":"15 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no relevant or material financial interests that relate to the research described in this paper","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This systematic review and meta-analysis did not involve direct interaction with human or animal subjects. All data analyzed were from previously published studies that were assumed to have adhered to ethical standards as stated by their respective authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed consent"}}]}}